212 related articles for article (PubMed ID: 30018082)
1. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Jenkins C; Luty SB; Maxson JE; Eide CA; Abel ML; Togiai C; Nemecek ER; Bottomly D; McWeeney SK; Wilmot B; Loriaux M; Chang BH; Tyner JW
Sci Signal; 2018 Jul; 11(539):. PubMed ID: 30018082
[TBL] [Abstract][Full Text] [Related]
2. In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia.
Chang BH; Thiel-Klare K; Tyner JW
bioRxiv; 2024 May; ():. PubMed ID: 38798550
[TBL] [Abstract][Full Text] [Related]
3. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
4. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
5. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
[TBL] [Abstract][Full Text] [Related]
6. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
[TBL] [Abstract][Full Text] [Related]
7. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.
Maxson JE; Abel ML; Wang J; Deng X; Reckel S; Luty SB; Sun H; Gorenstein J; Hughes SB; Bottomly D; Wilmot B; McWeeney SK; Radich J; Hantschel O; Middleton RE; Gray NS; Druker BJ; Tyner JW
Cancer Res; 2016 Jan; 76(1):127-38. PubMed ID: 26677978
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
9. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
Unal S; Cetin M; Kutlay NY; Elmas SA; Gumruk F; Tukun A; Tuncer M; Gurgey A
Ann Hematol; 2010 Apr; 89(4):359-64. PubMed ID: 19798502
[TBL] [Abstract][Full Text] [Related]
10. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD
Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436
[TBL] [Abstract][Full Text] [Related]
13. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.
Murray HC; Miller K; Brzozowski JS; Kahl RGS; Smith ND; Humphrey SJ; Dun MD; Verrills NM
Mol Cell Proteomics; 2023 Mar; 22(3):100503. PubMed ID: 36682716
[TBL] [Abstract][Full Text] [Related]
15. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
[TBL] [Abstract][Full Text] [Related]
16. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
[TBL] [Abstract][Full Text] [Related]
17. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM
Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997
[TBL] [Abstract][Full Text] [Related]
18. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.
Gritsman K; Yuzugullu H; Von T; Yan H; Clayton L; Fritsch C; Maira SM; Hollingworth G; Choi C; Khandan T; Paktinat M; Okabe RO; Roberts TM; Zhao JJ
J Clin Invest; 2014 Apr; 124(4):1794-809. PubMed ID: 24569456
[TBL] [Abstract][Full Text] [Related]
19. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
